OBJECTIVES: Matrix metalloproteinase-8 messenger RNA expression was previously found to be increased in whole blood of children with septic shock. The impact of this finding on the severity and inflammatory response to sepsis is unknown. Here, we investigate the relationship between matrix metalloproteinase-8 and disease severity in children with septic shock. We further corroborate the role of matrix metalloproteinase-8 in sepsis in a murine model. DESIGN: Retrospective observational clinical study and randomized controlled laboratory experiments. SETTING: Pediatric intensive care units and an animal research facility at an academic children's hospital. PATIENTS AND SUBJECTS: Patients age ≤10 yrs admitted to the intensive care unit with a diagnosis of septic shock. For laboratory studies, we utilized male mice deficient for matrix metalloproteinase-8 and male wild-type C57BL/6J mice. INTERVENTIONS: Blood from children with septic shock was analyzed for matrix metalloproteinase-8 messenger RNA expression and matrix metalloproteinase-8 activity, and correlated with disease severity based on mortality and degree of organ failure. A murine model of sepsis was used to explore the effect of genetic and pharmacologic inhibition of matrix metalloproteinase-8 on the inflammatory response to sepsis. Finally, activation of nuclear factor-κB was assessed both in vitro and in vivo. MEASUREMENTS AND MAIN RESULTS: Increased matrix metalloproteinase-8 mRNA expression and activity in septic shock correlates with decreased survival and increased organ failure in pediatric patients. Genetic and pharmacologic inhibition of matrix metalloproteinase-8 leads to improved survival and a blunted inflammatory profile in a murine model of sepsis. We also identify matrix metalloproteinase-8 as a direct in vitro activator of the proinflammatory transcription factor, nuclear factor-κB. CONCLUSIONS: Matrix metalloproteinase-8 is a novel modulator of inflammation during sepsis and a potential therapeutic target.
OBJECTIVES:Matrix metalloproteinase-8 messenger RNA expression was previously found to be increased in whole blood of children with septic shock. The impact of this finding on the severity and inflammatory response to sepsis is unknown. Here, we investigate the relationship between matrix metalloproteinase-8 and disease severity in children with septic shock. We further corroborate the role of matrix metalloproteinase-8 in sepsis in a murine model. DESIGN: Retrospective observational clinical study and randomized controlled laboratory experiments. SETTING: Pediatric intensive care units and an animal research facility at an academic children's hospital. PATIENTS AND SUBJECTS:Patients age ≤10 yrs admitted to the intensive care unit with a diagnosis of septic shock. For laboratory studies, we utilized male mice deficient for matrix metalloproteinase-8 and male wild-type C57BL/6J mice. INTERVENTIONS: Blood from children with septic shock was analyzed for matrix metalloproteinase-8 messenger RNA expression and matrix metalloproteinase-8 activity, and correlated with disease severity based on mortality and degree of organ failure. A murine model of sepsis was used to explore the effect of genetic and pharmacologic inhibition of matrix metalloproteinase-8 on the inflammatory response to sepsis. Finally, activation of nuclear factor-κB was assessed both in vitro and in vivo. MEASUREMENTS AND MAIN RESULTS: Increased matrix metalloproteinase-8 mRNA expression and activity in septic shock correlates with decreased survival and increased organ failure in pediatric patients. Genetic and pharmacologic inhibition of matrix metalloproteinase-8 leads to improved survival and a blunted inflammatory profile in a murine model of sepsis. We also identify matrix metalloproteinase-8 as a direct in vitro activator of the proinflammatory transcription factor, nuclear factor-κB. CONCLUSIONS:Matrix metalloproteinase-8 is a novel modulator of inflammation during sepsis and a potential therapeutic target.
Authors: Hector R Wong; Natalie Cvijanovich; Geoffrey L Allen; Richard Lin; Nick Anas; Keith Meyer; Robert J Freishtat; Marie Monaco; Kelli Odoms; Bhuvaneswari Sakthivel; Thomas P Shanley Journal: Crit Care Med Date: 2009-05 Impact factor: 7.598
Authors: Hector R Wong; Thomas P Shanley; Bhuvaneswari Sakthivel; Natalie Cvijanovich; Richard Lin; Geoffrey L Allen; Neal J Thomas; Allan Doctor; Meena Kalyanaraman; Nancy M Tofil; Scott Penfil; Marie Monaco; Mary Ann Tagavilla; Kelli Odoms; Katherine Dunsmore; Michael Barnes; Bruce J Aronow Journal: Physiol Genomics Date: 2007-03-20 Impact factor: 3.107
Authors: R Phillip Dellinger; Mitchell M Levy; Jean M Carlet; Julian Bion; Margaret M Parker; Roman Jaeschke; Konrad Reinhart; Derek C Angus; Christian Brun-Buisson; Richard Beale; Thierry Calandra; Jean-Francois Dhainaut; Herwig Gerlach; Maurene Harvey; John J Marini; John Marshall; Marco Ranieri; Graham Ramsay; Jonathan Sevransky; B Taylor Thompson; Sean Townsend; Jeffrey S Vender; Janice L Zimmerman; Jean-Louis Vincent Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: Natalie Cvijanovich; Thomas P Shanley; Richard Lin; Geoffrey L Allen; Neal J Thomas; Paul Checchia; Nick Anas; Robert J Freishtat; Marie Monaco; Kelli Odoms; Bhuvaneswari Sakthivel; Hector R Wong Journal: Physiol Genomics Date: 2008-05-06 Impact factor: 3.107
Authors: Alicia R Folgueras; Antonio Fueyo; Olivia García-Suárez; Jennifer Cox; Aurora Astudillo; Paolo Tortorella; Cristina Campestre; Ana Gutiérrez-Fernández; Miriam Fanjul-Fernández; Caroline J Pennington; Dylan R Edwards; Christopher M Overall; Carlos López-Otín Journal: J Biol Chem Date: 2008-02-01 Impact factor: 5.157
Authors: Thomas P Shanley; Natalie Cvijanovich; Richard Lin; Geoffrey L Allen; Neal J Thomas; Allan Doctor; Meena Kalyanaraman; Nancy M Tofil; Scott Penfil; Marie Monaco; Kelli Odoms; Michael Barnes; Bhuvaneswari Sakthivel; Bruce J Aronow; Hector R Wong Journal: Mol Med Date: 2007 Sep-Oct Impact factor: 6.354
Authors: Michele Y F Kong; Amit Gaggar; Yao Li; Margaret Winkler; J Edwin Blalock; J P Clancy Journal: Int J Med Sci Date: 2008-12-16 Impact factor: 3.738
Authors: Hector R Wong; Natalie Cvijanovich; Richard Lin; Geoffrey L Allen; Neal J Thomas; Douglas F Willson; Robert J Freishtat; Nick Anas; Keith Meyer; Paul A Checchia; Marie Monaco; Kelli Odom; Thomas P Shanley Journal: BMC Med Date: 2009-07-22 Impact factor: 8.775
Authors: Meghan C Daly; Sarah J Atkinson; Brian M Varisco; Lindsey Klingbeil; Paul Hake; Patrick Lahni; Giovanna Piraino; David Wu; Simon P Hogan; Basilia Zingarelli; Hector R Wong Journal: FASEB J Date: 2016-07-19 Impact factor: 5.191
Authors: Hector R Wong; Natalie Z Cvijanovich; Geoffrey L Allen; Neal J Thomas; Robert J Freishtat; Nick Anas; Keith Meyer; Paul A Checchia; Scott L Weiss; Thomas P Shanley; Michael T Bigham; Sharon Banschbach; Eileen Beckman; Kelli Harmon; Jerry J Zimmerman Journal: Am J Respir Crit Care Med Date: 2014-04-15 Impact factor: 21.405
Authors: Hector R Wong; Natalie Z Cvijanovich; Nick Anas; Geoffrey L Allen; Neal J Thomas; Michael T Bigham; Scott L Weiss; Julie Fitzgerald; Paul A Checchia; Keith Meyer; Thomas P Shanley; Michael Quasney; Mark Hall; Rainer Gedeit; Robert J Freishtat; Jeffrey Nowak; Shekhar S Raj; Shira Gertz; Emily Dawson; Kelli Howard; Kelli Harmon; Patrick Lahni; Erin Frank; Kimberly W Hart; Christopher J Lindsell Journal: Crit Care Med Date: 2015-08 Impact factor: 7.598
Authors: Sarah J Atkinson; Meghan Nolan; Lindsey Klingbeil; Kelli Harmon; Patrick Lahni; Basilia Zingarelli; Hector R Wong Journal: Crit Care Med Date: 2016-04 Impact factor: 7.598
Authors: Sarah J Atkinson; Brian M Varisco; Mary Sandquist; Meghan N Daly; Lindsey Klingbeil; Joshua W Kuethe; Emily F Midura; Kelli Harmon; Amy Opaka; Patrick Lahni; Giovanna Piraino; Paul Hake; Basilia Zingarelli; Joel E Mortenson; James L Wynn; Hector R Wong Journal: Mol Med Date: 2016-08-08 Impact factor: 6.354